Physician profile
Lygia Dsa
NPI 1235201518
$14,940.97
in general payments reported to CMS, 2019-2025
53 companies · $2,698 in 2025
The $2,698 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,398 · 2020: $1,930 · 2021: $2,294 · 2022: $1,919 · 2023: $1,746 · 2024: $1,956 · 2025: $2,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,400.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,476.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,906.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,385.73 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $1,218.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,018.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $953.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $633.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $545.91 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Amgen INC. | $529.74 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $525.62 | 2021-2025 | |
| Amarin Pharma, INC. | $425.41 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $386.77 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $244.25 | 2020-2022 | |
| Vivus LLC | $230.61 | 2019-2024 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $229.38 | 2021-2025 | Trintellix |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lygia Dsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.